颅内动脉粥样硬化性狭窄相关卒中血管成形及支架术后静脉替罗非班输注研究
回顾性病例系列研究纳入98例颅内动脉粥样硬化性狭窄相关大血管闭塞卒中患者,均行取栓后血管成形伴或不伴支架置入。其中30例术后持续静脉输注替罗非班12小时,68例未接受。结果显示替罗非班组早期再闭塞率显著低于对照组(3.3%对25%,P<0.001),出血并发症及90天良好预后率无显著差异,早期再闭塞与不良预后相关。
要点
- 术后静脉替罗非班12小时可降低治疗动脉早期再闭塞风险。
- 替罗非班未增加实质性血肿或症状性出血风险。
- 早期再闭塞患者90天良好预后率显著更低。
核心结论
- 颅内动脉粥样硬化性狭窄相关大血管闭塞卒中患者急诊血管成形伴或不伴支架置入后,静脉替罗非班使用12小时与治疗动脉早期再闭塞风险降低相关,且不增加出血风险。
- 早期再闭塞与此类患者的不良预后相关。
研究设计与样本
- 回顾性病例系列研究,纳入98例接受取栓后血管成形伴或不伴支架置入的颅内动脉粥样硬化性狭窄相关大血管闭塞卒中患者。
- 患者分为静脉替罗非班组(术后持续静脉输注替罗非班12小时,n=30)和对照组(术后未接受静脉替罗非班,n=68)。
主要发现
- 98例患者中18例(18.4%)发生早期再闭塞。
- 静脉替罗非班组早期再闭塞率显著低于对照组(3.3%对25%,P<0.001)。
- 两组实质性血肿、症状性出血、90天良好预后及死亡率均无显著差异。
- 多因素logistic分析显示,未使用静脉替罗非班是早期再闭塞的唯一独立预测因素(OR=9.212,95%CI 1.155-73.495,P=0.036)。
- 发生早期再闭塞的患者90天良好预后(改良Rankin量表评分0-2分)比例显著低于未发生者(16.7%对72.5%,P<0.001)。
临床怎么用
- 对于颅内动脉粥样硬化性狭窄相关大血管闭塞卒中患者,急诊血管成形伴或不伴支架置入后,可考虑静脉输注替罗非班12小时以降低早期再闭塞风险。
- 术后需关注早期再闭塞的监测,因其与不良功能预后相关。
局限性
- 本研究为回顾性病例系列研究,样本量较小(共98例),可能存在选择偏倚和混杂因素。
- 替罗非班组仅30例,对照组68例,组间基线特征未在摘要中详细报告,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This study aimed to investigate the effectiveness and safety of intravenous infusion of tirofiban after emergent angioplasty with or without stenting in patients with intracranial atherosclerotic stenosis-related large-vessel occlusion stroke. METHODS: We performed a retrospective case series study of 98 patients who underwent thrombectomy followed by angioplasty with or without stenting to treat intracranial atherosclerotic stenosis-related large-vessel occlusion. Patients were divided into 2 groups: those who received continuous intravenous infusion of tirofiban for 12 hours after procedure (intravenous tirofiban group, n=30) and those who did not receive postprocedural intravenous tirofiban (control group, n=68). The following treatment outcomes in the 2 groups were compared: early reocclusion of treated arteries on computed tomography angiography, parenchymal hematoma, symptomatic hemorrhage, and 90-day functional outcome. RESULTS: Early reocclusion occurred in 18 patients (18.4%). The rate of early reocclusion was significantly lower in the intravenous tirofiban group than in the control group (3.3% versus 25%, P<0.001). The rates of parenchymal hematoma, symptomatic hemorrhage, 90-day good outcome, and mortality were not significantly different between the 2 groups. In multivariate logistic analysis, the only independent predictor of early reocclusion was no use of intravenous tirofiban (odds ratio, 9.212 [95% CI, 1.155-73.495], P=0.036). A good outcome (90-day modified Rankin Scale score of 0-2) was significantly less frequent in patients with early reocclusion than in those without it (16.7% versus 72.5%, P<0.001). CONCLUSIONS: The use of intravenous tirofiban for 12 hours was associated with decreased risk of early reocclusion of treated arteries, with no increased risk of hemorrhage after emergent angioplasty, with or without stenting, in patients with intracranial atherosclerotic stenosis-related large-vessel occlusion stroke. Early reocclusion was associated with a poor outcome in such cases.
引用
- Baek BH, Yoon W, Lee YY, et al. Intravenous Tirofiban Infusion After Angioplasty and Stenting in Intracranial Atherosclerotic Stenosis-Related Stroke. Stroke. 2021. PMID: 33793319. doi:10.1161/STROKEAHA.120.033551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。